Résumé
To explore the therapeutic effect and safety of target-dose metoprolol in treating chronic heart failure [CHF] patients complicated with diabetes mellitus [DM]. One hundred and fifty-four elderly patients were randomly divided into an observation group and a control group [n=77], which were treated with target-dose metoprolol and conventional therapy, and routinely treated respectively. The New York Heart Association [NYHA] classification, left ventricular end-systolic diameter [LVESD], left ventricular end-diastolic diameter [LVEDD], left ventricular ejection fraction [LVEF], 6-min walking distance and medication safety of the two groups were compared. Compared with the results before treatment, the NYHA classification, LVESD, LVEDD, LVEF and 6-minutes walking distance of both groups were significantly improved [P < 0.05], with significantly better results in the observation group than those in the control group after treatment [P < 0.05]. In the 6 months of follow-up, the incidence of cardiac events in the observation group [3.90%] was significantly lower than that of the control group [14.29%] [P < 0.05]. The levels of average fasting blood sugar and glycosylated hemoglobin in the groups showed no significant differences [P > 0.05]. Treating CHF patients complicated with DM with target-dose metoprolol can obviously boost the cardiac function and exercise tolerance, leading to satisfactory clinical therapeutic effect, high security and moderate tolerance
Résumé
Serum cytokine concentrations were determined in patients with Graves'disease(GD)before and after treatment of thiamazole.Serum soluble interleukin-2 receptor(sIL-2R)level was markedly raised before treatment as compared with normal subjects and returned to normal after 3 month therapy.Serum IL-8 level was lowered in GD patients and showed no change after 3 month therapy.No relationship between IL-8 and other markers was found.Serum IL-1?,IL-6 and TNF-?levels in GD patients showed no difference with those in normal controls.
Résumé
The aim of this Post-Marketing Surveillance study was to assess efficacy,safety and acceptance of acarbose treatment in Chinese type 2 diabetic patients under day-to-day practice conditions.A total of 2 480 patients were enrolled by 231 physicians throughout China into an open,prospective,uncontrolled,non- randomised,multi-centre study.Main efficacy parameters were the changes in fasting and postprandial blood glucose concentrations as well as in HbA-(1C) levels after acarbose treatment.The majority of patients had been previously treated with other oral anti-diabetic medication or insulin and received concomitant anti-diabetics during the mean observation period of 13.5 weeks.Most patients started on a daily acarbose dose of 50 mg t.i.d. Acarbose treatment reduced fasting blood glucose concentrations by 56.1 mg/dl ( 18 mg/dl glucose = 1 mmol/L glucose) and 2h-postprandial values by 111.3 mg/dl over the study period.HbA-(1C) decreased by 1.9% and body weight by 0.9 kg.76 acarbose-relatod adverse events occurred;two patients experienced serious adverse events. The attending physicians assessed treatment efficacy as“very good”or“good”for 90.1% of the patients, tolcrability for 89.1% and acarbose acceptance for 87.1% of the patients.Acarbose is efficacious,safe and well accepted by Chinese type 2 diabetic patients under day-to-day routine conditions,both as anti-diabetic mono- therapy and in combination with other anti-dlabetic drugs.